Protease-Antiprotease Interactions and the Rationale for Therapeutic Protease Inhibitors

References

• Go VLW, Gardner J D, Brooks F P, Lebenthal E, Di Magno E P, Scheele G A. The exocrine pancreas: biology, pathobiology, and diseases. Raven Press, New York 1986
   Google Scholar
• Wilson C, Shenkin A, Imrie C. Role of protease-antiprotease balance in peritoneal exudate during acute pancreatitis. Br J Surg 1991; 78: 78–81
   Google Scholar
• Barret A J, Starkey P M. The interaction of α2-macroglobulin with proteases. Characteristics and specificity of the reaction and a hypothesis concerning its molecular action. Biochem J 1973; 133: 709–24
   PubMed Web of Science ®Google Scholar
• Lasson Å, Ohlsson K. Protease inhibitors in acute pancreatitis. Correlation between biochemical changes and clinical course. Scand J Gastroenterol 1984; 19: 779–86
   PubMed Web of Science ®Google Scholar
• Balldin G. On protease-antiprotease imbalance with special reference to the protective role of protease inhibitors in acute pancreatitis. Med Diss Malmö. General Hospital, Sweden 1980
   Google Scholar
• Steinberg W M. Predictors of severity of acute pancreatitis. Gastroenterol Clin N Am 1990; 19: 849–61
   PubMedGoogle Scholar
• Buchler M, Malfertheiner P, Schoetensack C, Uhl W, Beger H G. Sensitivity of antiproteases complement factors and C-reactive protein in detecting pancreatic necrosis: results of a prospective study. Int J Pancreatol 1986; 1: 227–35
   PubMedGoogle Scholar
• McMahon M J, Bowen M, Mayer A D, Cooper E H. Relation of α2-macroglobulin and other antiproteases to the clinical features of acute pancreatitis. Am J Surg 1984; 147: 164–70
   PubMed Web of Science ®Google Scholar
• Uhl W, Büchler M, Malfertheiner P, Martini M, Beger H G. PMN-elastase in comparison with CRP antiproteases and LDH as indicators of necrosis in human acute pancreatitis. Pancreas 1991; 6: 253–9
   PubMed Web of Science ®Google Scholar
• Steer M, Meldolesi J, Figarella C. Acute pancreatitis: The role of lysosomes. Dig Dis Sci 1984; 29: 934–8
   PubMed Web of Science ®Google Scholar
• Figarella C, Amouric M, Gui-Crotte O. Enzyme activation and liberation: intracellular/extracellular events. Acute pancreatitis, H G Beger, M Buchler. Springer Verlag, Berlin 1987; 53–60
   Google Scholar
• Yamaguchi H, Kimura T, Mimura K, Nawata H. Activation of proteases in caerulein-induced pancreatitis. Pancreas 1989; 4: 565–71
   PubMed Web of Science ®Google Scholar
• Bialek R, Willemer S, Arnold R, Adler G. Evidence of intracellular activation of serine proteases in acute caerulein-induced pancreatitis in rats. Scand J Gastroenterol 1991; 26: 190–6
   PubMed Web of Science ®Google Scholar
• Leach S D, Modlin J M, Scheele G A, Gorelick F S. Intracellular activation of digestive zymogens in rat pancreatic acini. J Clin Invest 1991; 87: 362–6
   PubMed Web of Science ®Google Scholar
• Steinberg W M, Schlesselmann S E. Treatment of acute pancreatitis: comparison of animal and human studies. Gastroenterology 1987; 93: 1420–7
   PubMed Web of Science ®Google Scholar
• Trapnell J E, Rigby C C, Talbot C H, Duncan EHL. A controlled trial of trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61: 177–82
   PubMed Web of Science ®Google Scholar
• Cox A G. Death from acute pancreatitis: MRC multicentre trial of glucagon and aprotinin. Lancet 1977; 24: 632–5
   Google Scholar
• Imrie C W, Benjamin I S, Ferguson J C, McKay A J, Mackenzie I M, O'Neill J, Blumgart L H. A single centre double blind trial of trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65: 337–41
   PubMed Web of Science ®Google Scholar
• Tsukiyama Y, Kubota Y, Maeda S. A study of Foy in the treatment of pancreatitis. Jap J Clin Exp Med 1973; 50: 12–21
   Google Scholar
• Freise J, Melzer P, Schmidt F. Gabexat-mesilat in der Behandlung der akuten Pankreatitis. Z Gastroenterol 1986; 24: 200–11
   Google Scholar
• Goebell H (German pancreatitis study group). Multicentre double-blind study of gabexate mesilate (Foy), given intravenously in low dose in acute pancreatitis (Abstract). Digestion 1988; 40: 83
   Google Scholar
• Kunze H, Bohn E, Damerau B. Effects of antiinfiammatory serine esterase inhibitor, Foy, on phospholipase A2 (EC 3.1.1.4) activity in rabbit's polymorphonuclear leukocytes. Pharmacol Res Commun 1983; 15: 869–78
   Google Scholar
• Hesse B, Lankisch P G, Kunze H. Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2. Pharmacol Res Commun 1984; 16: 637–5
   Google Scholar
• Schädlich H, Büchler M, Beger H G. Inhibition of porcine phospholipase A2 activation by gabexate mesilate. Klin Wochenschr 1989; 67: 160–2
   Google Scholar
• Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis. Int J Pancreatol 1993; 14: 117–24
   PubMedGoogle Scholar
• Büchler M, Malfertheiner P, Uhl W. Gabexat-mesilat in der Therapie der akuten Pankreatitis. Multicenter Studie zur Verträglichkeit einer hohen intravenösen Dosis (4 g/Tag). Med Klin 1988; 83: 320–324
   Google Scholar
• Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger H G. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104: 1165–1170
   PubMed Web of Science ®Google Scholar
• Valderrama R, Pérez-Mateo M, Navarro S, Vàzquez N, Sanjose L, Adriàn M J, Estruch J. Multicentre double-blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51: 65–70
   Google Scholar
• Leese T, Holliday M, Watkins M, Neoptolemos J P, Thomas W M, Attard A. A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl 1991; 73: 207–214
   Google Scholar